SSA
BCTX

SSA Swiss Advisors’s Briacell Therapeutics BCTX Stock Holding History

SSA Swiss Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37
Closed -$264 – 95
2025
Q4 		$264 Buy
+37
New +$390 ﹤0.01% 102

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

SSA Swiss Advisors's BCTX Position: Q1 2026 in Review

SSA Swiss Advisors sold out of Briacell Therapeutics (BCTX) in Q1 2026, closing a stake of 37 shares — an estimated $264 sold.

SSA Swiss Advisors first reported a position in BCTX in Q4 2025 and held it in 1 quarter. The position peaked at $264 in Q4 2025. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • SSA Swiss Advisors reported no remaining Briacell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SSA Swiss Advisors sold 37 Briacell Therapeutics shares in Q1 2026, an estimated $264.
  • SSA Swiss Advisors first reported a position in Briacell Therapeutics in Q4 2025 and held it in 1 quarter.
  • SSA Swiss Advisors's Briacell Therapeutics position peaked at $264 in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on SSA Swiss Advisors's 13F filing for Q1 2026, filed 21 Jul 2026.